Biofil Chemicals & Pharmaceuticals Ratios

Biofil Chemicals & Pharmaceuticals Ltd Ratios

The Biofil Chemicals & Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Biofil Chemicals & Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Biofil Chemicals & Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Biofil Chemicals & Pharmaceuticals Ltd (NSE: BIOFILCHEM, BSE: 524396) is currently trading at ₹30.56, with a market capitalization of ₹493.42M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Biofil Chemicals & Pharmaceuticals Ltd remains a key stock for fundamental analysis using Biofil Chemicals & Pharmaceuticals Ltd Ratios.

Biofil Chemicals & Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Biofil Chemicals & Pharmaceuticals Ltd P/E ratio currently stands at 120.02, making it one of the most tracked metrics in Biofil Chemicals & Pharmaceuticals Ltd Ratios.

Historically, the Biofil Chemicals & Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 120.02
• 2023: 138.50
• 2022: 120.33
• 2021: 134.67
• 2020: 86.06

The decline in Biofil Chemicals & Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Biofil Chemicals & Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.56.

Historical P/B trend:

• 2024: 3.56
• 2023: 5.40
• 2022: 3.90
• 2021: 5.59

Biofil Chemicals & Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Biofil Chemicals & Pharmaceuticals Ltd P/S ratio currently stands at 2, an important part of Biofil Chemicals & Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2
• 2023: 2.45
• 2022: 2.25
• 2021: 4.20

A stable or declining Biofil Chemicals & Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Biofil Chemicals & Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Biofil Chemicals & Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Biofil Chemicals & Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 41.76
• 2022: 0
• 2021: 0
• 2020: 102.45

The declining Biofil Chemicals & Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Biofil Chemicals & Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Biofil Chemicals & Pharmaceuticals Ltd EV currently stands at ₹671.5M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 671.5M
• 2023: 963.84M
• 2022: 679.23M
• 2021: 943.82M

Biofil Chemicals & Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Biofil Chemicals & Pharmaceuticals Ltd EV/EBITDA ratio is currently 79.24, a key metric in Biofil Chemicals & Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 79.24
• 2023: 118.05
• 2022: 58.17
• 2021: 70.82

Stable Biofil Chemicals & Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Biofil Chemicals & Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Biofil Chemicals & Pharmaceuticals Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.02
• 2022: 0.03
• 2021: 0.03

Biofil Chemicals & Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Biofil Chemicals & Pharmaceuticals Ltd ROE currently stands at 3.02%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 3.02
• 2023: 4
• 2022: 3.28
• 2021: 4.24

Declining ROE indicates pressure on profitability.

Biofil Chemicals & Pharmaceuticals Ltd Ratios Analysis Summary

The Biofil Chemicals & Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Biofil Chemicals & Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Biofil Chemicals & Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.